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Abstract
Background: We investigated the molecular basis of primary open-angle glaucoma (POAG) using
Opticin (OPTC) as a candidate gene on the basis of its expression in the trabecular meshwork cells
involved in the disease pathogenesis. Two hundred POAG patients and 100 controls were enrolled
in this study. The coding sequence of OPTC was amplified by PCR from genomic DNA of POAG
patients, followed by SSCP, DHPLC and DNA sequencing. Subsequent bioinformatic analysis, site-
directed mutagenesis, quantitative RT-PCR and western blot experiments were performed to
address the functional significance of a 'silent' change in the OPTC coding region while screening for
mutations in POAG patients.
Results:  We detected two missense (p.Glu66Gly & p.Ile89Thr) and one silent change
(p.Phe162Phe; c.602 C>T) that was present in 3 different patients but in none of the 100 controls
screened. The mutant (c.602T) mRNA was predicted to have remarkably different secondary
structure compared to the wild-type transcript by in silico approaches. Subsequent wet-lab
experiments showed lower expression of the gene both at the mRNA and protein levels.
Conclusion: Our study suggests OPTC as a candidate gene for POAG. Further, it highlights the
importance of investigating the 'silent' variations for functional implication that might not be
apparent from only in silico analysis.
Background
Glaucoma comprises a group of neurodegenerative disor-
ders of the eye characterized by a progressive loss of reti-
nal ganglion cells and atrophy of the optic nerve [1]. With
a multifactoral etiology, glaucoma account for 12.3%
blindness worldwide [2]. Primary Open Angle Glaucoma
(POAG) is the most common form of the disease [3]
where the vision is lost in a progressive manner and, if
untreated, results in bilateral blindness. About 33 million
people are affected with POAG [3]. It usually gives no
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indication to the patient until there is appreciable and
irreversible loss of the field of vision. Normal Tension
Glaucoma (NTG), juvenile glaucoma, chronic open angle
glaucoma are common subtypes of POAG. So far three
different genes, Myocilin (MYOC) and Optineurin (OPTN)
and WDR36 [4-6] and eleven additional chromosomal
loci have been reported to be linked to POAG [5-14]. Also
digenic form of the disease has been reported based on
mutations in MYOC  and  CYP1B1  genes [15].
Recent studies have implicated genes that are expressed in
the optic nerve head (PAD2) [16] and the trabecular
meshwork (Cochlin) [17] to be involved in POAG patho-
genesis. We examined Opticin (OPTC) as a candidate for
POAG since it is expressed in the trabecular meshwork –
the ocular site where the POAG related pathogenesis
occurs [18]. OPTC encodes a protein of 332 amino acids
and a member of class III small leucin-rich repeat protein
(SLRP) family [19,20]. The gene is located on chromo-
some 1q31-q32 within an age-related macular degenera-
tion (AMD) susceptibility locus [21,22] and examined for
nucleotide variants in both AMD and POAG patients [18].
We, therefore, screened OPTC as candidate in 200 eastern
Indian POAG patients to decipher the underlying com-
plexity of the disease and attempted to broaden our
understanding regarding its pathogenesis.
Results
Mutation and SNP profile in OPTC
A novel change (c.313A>G) that would result in a non-
conservative substitution (p.Glu66Gly) was detected in
exon 2 of OPTC (Fig 1B) in a sporadic patient in hetero-
zygous condition (Table 1). The suspect allele was not
detected in any of 100 control individuals screened for
variation in the OPTC. In addition, the encoded amino
acid residue (p.Glu66) being affected is conserved in
higher vertebrates (i.e. human, mouse, dog, pig, cow &
duck) among all the species for which the sequence of
OPTC homologue is available (Fig 2A). Also, a SIFT score
of 0.03 suggests functional relevance of the protein result-
ing from the variant allele (Table 1). The patient (36 years
old male patient, GL 131 in Table 1) had a total loss of
vision, with no PL (perception of light) in the right eye
and with the ability to count fingers at one-foot distance
with PR (projection of rays) in the left eye. When we first
met the patient he had already undergone trabeculectomy
in his right eye and before the surgery he almost lost the
vision in the right eye. He had maximum IOP of 16 and
42 mm of Hg in the right & the left eye, respectively. There
was no previous record for IOP in his right eye, and the
value at post-operative stage was 16 mm of Hg. The cup to
disc ratio could not be determined in the right eye due to
presence of cataract and hazy media and 0.8 in the left eye.
Gonioscopy revealed open angle (grade III – IV). This
nucleotide change was not found in 100 healthy control
samples (Table 1).
The second nucleotide alteration (c.382 T>C, p.Ile89Thr;
Fig. 1B) was identified in heterozygous condition in exon
3 of OPTC gene of a 65 year old male sporadic patient
(GL77 in Table 1) who was also heterozygous for a
reported mutation (c.1960 G>A; Arg545Gln) in OPTN
[23]. The IOP of this patient, recorded in aided condition,
was 25 & 18 mm of Hg in the right and the left eye, respec-
tively. The lower IOP value in the left eye was due to the
medication used. Unlike the other variant (c.313A>G),
the amino acid residue (p.Ile89) for the wild type allele
(c.382 T) for this nucleotide change (c.382 T>C) is con-
served only in human and mouse (Fig 2A), and gives a
non-significant (0.66) SIFT score (Table 1). Though the
nucleotide change was not identified in 100 control indi-
viduals, it appears unlikely to be pathogenic.
Both the nucleotide variants (c.313A>G, p.Glu66Gly &
c.382 T>C, p.Ile89Thr) were examined for aberrant mRNA
structure and splice variation, if any, using the in silico
tools (RNAdraw, ESE finder and RESQUE ESE) but did
not find any significant variation in predicted RNA struc-
ture or splice alteration. Patients carrying these two novel
changes were sporadic in nature and their family mem-
bers were not available to determine the disease status in
the relatives and the segregation pattern of the variant
alleles.
A reported SNP [18] (c.919 T>C; p.Leu268Pro) identified
in a patient (Fig 1B) was scored in other patients and con-
trols by Bpu10I RFLP assay. However, no significant dif-
ference was observed between the patients and control
subjects either in allele frequencies (p = 0.247 under df =
1) or genotype distribution (p = 0.4136 under df = 2). The
heterozygosity of the SNP in patient and control groups
was found to be 0.25 and 0.19, respectively.
Functional importance of a 'silent' change in OPTC 
coding region
A novel change (c.602 C>T) in exon 4 of OPTC (Fig 1B),
that on conceptual translation would remain silent
(p.Phe162Phe), was detected in heterozygous condition
in a sporadic patient but none in 100 control individuals
(Table 1). The patient, a 46 year old male patient (GL 42
in Table 1) with unilateral glaucoma in the right eye, pre-
sented with a visual acuity of 6/18 (unaided), IOP of 17
mm of Hg and a cup to disc ratio of 0.8. Gonioscopy
revealed open angle (grade III – IV) and a mature and
complicated cataract in the right eye. The visual field anal-
ysis in the right eye showed localized defect near fixation
point in the infero-temporal quadrant and tubular vision.
He was under anti-glaucoma medication in the right eye.
The left eye was traumatic with a history of penetratingBMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
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injury at ages of 12 and 14 years. There was no perception
of light on projection in the left eye. Incidentally younger
brother (GL 116) of the proband (GL42) is also hetero-
zygous for the 'silent' change (c.602 C>T) who was a 'sus-
pect' for POAG with raised IOP but no significant C:D
ratio or visual field change. However, this individual later
did not come for follow up and could not be traced
despite best efforts.  No splice alteration was predicted to
be caused by the variant allele as determined by in silico
analysis using ESE finder and RESQUE ESE.
Interestingly, though the variant nucleotide is the third
base of the codon and prone to wobble, at mRNA level, it
is evolutionarily conserved in all higher vertebrates
among the species for which the sequence of OPTC
homologue is available (Fig 2B). There are two codons
Table 1: Clinical data of POAG patients having sequence changes in OPTC
Patient ID 
(age at 
diagnosis)
Location Mutation SIFT  scorea Glaucoma 
subtype
Visual acuity 
RE, LE
IOP (mm of 
Hg) RE, LE
C:D ratio RE, 
LE
Visual field changes
GL131 (37 yrs) Exon 2 Glu66Gly* 0.03 JOAG No PL, FC(1ft) 
& PL+ PR
16b, 42 media hazy, 0.8 Glaucomatous field changes
GL77 (65 yrs) Exon 3 Ile89Thr* 0.66 POAG 6/12, 6/6 25,18 0.8, 0.7 Glaucomatous field changes
GL42 (32 yrs) Exon 4 Phe162Phe* NA JOAG 6/18, NoPL 17, ND 0.8, ND Localized defect near fixation 
point in the infero-temporal 
quadrant and tubular vision in 
right eye
*Novel variant; aSIFT score predicts phenotypic effect; < 0.05 predicted to be deleterious, =/>0.05 tolerated [31]; bThe IOP in right eye of GL131 
is post-operative value.
The cDNA numbers correspond to Genbank accession number NM_014359
Abbreviations used: RE: right eye and LE: left eye; IOP: Intra ocular pressure; C:D ratio: cup to disc ratio; PO: post operative; BE: both eye; PL: 
perception of light; PR: projection of rays; FC: finger counting; ND: not detectable due to Band keratopathy in left eye
Nucleotide variants in OPTC Figure 1
Nucleotide variants in OPTC. (A): Gene structure of Opticin. Bars and lines represent the exons and introns, respectively. 
Exon numbers and mutation/polymorphism therein are indicated. Within exons shaded and open boxes show coding 
sequences and untranslated regions, respectively. (B): SSCP images along with chromatograms showing nucleotide changes in 
OPTC of POAG patients identified in Table 1.BMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
Page 4 of 10
(page number not for citation purposes)
(TTC & TTT) for Phe that, as per latest NCBI data have no
significant difference in the relative usage in human pro-
teins (i.e. 20 vs 17). This provoked us to look for the sta-
bility of this variant at mRNA level using RNAdraw. We
observed that though the variation of structure energy (8
kJ) between variant (-1525.24kJ) and normal OPTC
mRNA (-1533.11kJ) did not appear to be significant
enough affecting stability of the variant, a large change in
the secondary structure of mRNA was apparent (Fig 3). We
reasoned that an altered structure of the mRNA, if any,
might influence the efficiency of translation of the tran-
script due to a single nucleotide change (c.602 C>T). In
the NCBI SNP database we found another silent change
(c.518C>T, p.Leu134Leu, rs747814) 84 bp upstream but
not in the close proximity of the silent change (c.602C>T)
under investigation. The 5' silent SNP (c.518C>T) was
tested for change in the mRNA secondary structures
between the two alleles and no significant variation was
observed. To find out its downstream implication, the var-
iant (c.602T) was created by site directed mutagenesis in
the Opticin cDNA cloned in pEGFPN1 and subsequently
transfected both wild type (c.602C) and variant (c.602T)
in the retinal pigment epithelium (RPE) cells. Transfec-
tion experiments were done in 3 to 4 times followed by
subsequent quantitative RT-PCR (QRT) and western blot
analysis. From the QRT data it was evident that the mRNA
amount of the silent variant (c.602T) was lower (the dif-
ference in ΔΔCT value between c.602C and c.602T was
Evolutionary conservation status of the silent change at cDNA level and other two nucleotide variants at protein level found in  OPTC Figure 2
Evolutionary conservation status of the silent change at cDNA level and other two nucleotide variants at pro-
tein level found in OPTC. (A): Multiple sequence alignment of opticin protein showing the conservation status of p.Glu66 
(c.313A>G) residue and p.Ile89 (c.382T>C) residue across different vertebrate species. The sources of the sequences are 
NCBI: NP_055174.1 (human), XP_001102193.1 (monkey), NP_473417.1 (mouse), XP_222641.4 (rat), NP_991339.1 (cow), 
NP_001003056.1 (dog), NP_999173.1 (pig), NP_989804.1 (duck), NP_001016499.1 (Xenopus), ABB53599.1 (zebrafish). Except 
two lower vertebrates (Xenopus and zebrafish), p.66 (c.313A>G) is conserved in all higher vertebrate species, while p.Ile89 
(c.382T>C) is conserved only in human and mouse. In both cases, multiple sequence alignment was done using ClustalW of 
EMBL-EBI [39] (B): Multiple sequence alignment of OPTC cDNA shows conservation of the wobble base for p.Phe162 which is 
altered (C>T) in case of a POAG patient (GL42 in Table 1). The sources of the sequences are GenBank: NM_014359 (human), 
XM_001102193.1 (monkey), NM_054076.1 (mouse), XM_001061460.1 (rat), NM_205770.1 (cow), NM_001003056.1 (dog), 
NM_214008.1 (pig), NM_204473.1 (duck), NM_001016499.2 (Xenopus) and NM_001003583.1 (zebrafish). Also, corresponding 
amino acid sequence of human opticin (NP_055174.1) is given above; except two lower vertebrates (Xenopus and zebrafish), 
c.602C (p.Phe162) is conserved in all higher vertebrate species.BMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
Page 5 of 10
(page number not for citation purposes)
found to be 3.73) with respect to wild type (c.602C) (Fig
4A). Further, western blot analysis using anti-opticin anti-
body clearly showed that expression of the mutant protein
(c.602T) was lower (43%) compared to the native protein
(c.602C) (Fig 4B &4C). Both the GFP fused proteins were
normalized with the endogenous Opticin in RPE cells.
Discussion
The complex nature of POAG warrants identification of
genes that are expressed in the TM tissues, retinal ganglion
cells and optic nerve head in order to understand the
underlying molecular mechanisms leading to the disease
pathogenesis. Recent studies in this direction have identi-
fied genes that could be potentially involved in the disease
pathology [1]. Among these candidate genes, Myocilin
mutations account for about 3–4% of open angle glau-
coma (OAG) [4], with the Gln368Stop nonsense variant
accounting for many, but not all, of the adult onset OAG
cases [24,25]. Most of the other MYOC variants are mis-
sense mutations usually associated with a JOAG pheno-
type. A small number of mutations in Optineurin  are
found in families in which most affected individuals have
NTG [23]. Mutations in WDR36 have been observed to be
mostly associated with adult POAG patients with high lev-
els of IOP [6]. Much remains to be understood about the
underlying mechanisms by which mutations in these
genes predispose to glaucoma and most cases cannot be
accounted for by these three genes. In a previous study,
OPTC was examined in 142 patients with ocular problem:
45 with age-related macular degeneration (AMD), 10 with
AMD plus POAG or NTG, and 87 individuals with POAG
or NTG alone [18]– this screening effort yielded four
sequence variations. On screening of the gene in 200
POAG patients of eastern India, we detected two nucle-
otide variants with potential to be causal to the pathogen-
esis for the disease, a rare variant and a SNP. The two
novel, missense variants were absent in 100 controls sug-
gesting potential role of the variant alleles in POAG.
While our study suggests involvement of OPTC in causa-
tion of POAG, we could not directly implicate the gene for
lack of current knowledge on its biological function.
A translationally silent variation (c 602C>T,
p.Phe162Phe) present in OPTC of a POAG patient but
none of the controls suggested potential biological rele-
vance of apparently innocuous change. Though in silico
analysis does not suggest alteration of splice site resulting
from the nucleotide change, wet lab experiments includ-
Difference in the mRNA secondary structure between c.602C and c.602T variant in OPTC Figure 3
Difference in the mRNA secondary structure between c.602C and c.602T variant in OPTC. Both the structures 
were predicted using the default parameter of RNAdraw (calculation temp. 37°C). Region of the mRNA harboring the variant 
nucleotide (indicated by arrow) has been enlarged for both the alleles to demonstrate the local structural alteration as pre-
dicted by RNAdraw.BMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
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ing construction of minigene and its analysis by transcrip-
tion is necessary for a final answer. Although, mRNA
secondary structure prediction analysis did not show a
large alteration of stability as measured by change in the
structure energy, the structural alteration appeared to be
impressive. But a clear observation based on the loop
structure and its stability is not apparent to offer further
explanation. However, the influence of RNA secondary
structure on gene expression and pattern of interaction
has been already reported in prokaryotic system [26] and
HIV [27,28]. Therefore, it is possible that the lower trans-
lational efficiency of the mutant allele might be due to
lower stability of the mutant mRNA or, in a less likely sit-
uation, structural hindrance in translation. The QRT data
demonstrates lower amount of mutant mRNA available
for translation. The variation in the stability of the
wildtype and mutant mRNA could be measured by lim-
ited RNAse digestion or in vitro transcription techniques.
It is worthwhile to mention here that it remains important
to show functional correlation of the suspected opticin
variants with glaucoma pathogenesis to further substanti-
ate role of the gene in the disease process.
A direct correlation of the OPTC silent change, described
in this article, with POAG would require demonstration
of either cosegregation of the variant allele with POAG in
a family or identification of the nucleotide change in mul-
tiple unrelated patients. Presence of the 'functional silent
variation' (c.602 C>T) in the POAG 'suspect' younger sib
of the patient, however, supports further of its potential
association with POAG.
Conclusion
We detected two novel missense alterations along with a
'silent' change in OPTC; among these p.Glu66Gly and the
silent change (p.Phe162Phe) are likely to be associated
with glaucomatous phenotype. The expression of the pro-
tein from the rare allele (c.602T) of the 'silent' change
(c.602C>T) was significantly lower. Therefore, our study
highlights the importance of investigating the 'silent'
mutations for functional implication that might not be
Difference in mRNA and protein expression levels between c.602T variants in OPTC Figure 4
Difference in mRNA and protein expression levels between c.602C and c.602T variants in OPTC. (A): Quantiative 
RT-PCR showing expression of c.602C and c.602T in mRNA level. The difference in mRNA expression is represented by 
ΔΔCT value. (B): Western blot of two variants of Opticin core protein fused with GFP as well as endogenous Opticin in RPE 
cells. UT represents the untransfected RPE cells. (C): Bar diagram showing the mean ± SD of densitometric scanning of west-
ern blots done thrice, that indicates much less expression of OPTC-c.602T variant (43%) than the normal one (OPTC-c.602C). 
Expression of transfected protein (Opticin-GFP) was normalized with endogenous Opticin.BMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
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apparent from only in silico analysis. Additional studies on
role of OPTC in POAG would provide better understand-
ing of the function of the gene in the POAG related patho-
genesis.
Methods
Selection of subjects and collection of blood samples
Two hundred unrelated POAG patients, comprising 156
sporadic cases and 44 with family history, presenting at
the Regional Institute of Ophthalmology and Dristi
Pradip Kolkata, India, were enrolled in this study. The
inclusion criteria involved significant cupping of the optic
disc with or without peripapillary changes and presence of
open angles on gonioscopy. Cupping >0.6 raised suspi-
cion of glaucoma. If cupping was associated with inferior
notching of rim of disc, it was considered to be highly sus-
picious of being glaucomatous. Also, large cup in a small
disc raises suspicion of glaucoma. However, often cup
with large disc may be considered as physiological cup-
ping and hence normal. Therefore, it was always con-
firmed by typical reproducible visual field changes and
investigating retinal nerve fiber configuration through
direct evaluation of retinal nerve fiber layer (RNFL). Sub-
jects meeting the above criteria with elevated IOP were
enrolled as having high tension glaucoma (HTG), and
those without elevated IOP were enrolled as patients with
normal tension glaucoma (NTG). Patients with history of
inflammation or ocular trauma and other systemic condi-
tions were excluded. Based on these criteria, among the
patients 34 had juvenile onset open-angle glaucoma (< 30
years of age) and 166 had adult-onset open-angle glau-
coma including 87 NTG cases. The mean age of diagnosis
of the patients was 52.43 ± 19.33 years with a range vary-
ing between 7 years and 84 years. Diagnosis of POAG was
confirmed by three of us (SKDT, AKB and AS). Ocular
examinations involved measurement of intra ocular pres-
sure (IOP) by Applanation tonometer (Goldmann).
Gonioscopy by Goldmann 3-mirror gonioscope (Shaffer's
grading), optic disc evaluation (+78D lens), fundoscopy
and visual fields testing (Humphrey's automated perime-
ter).
One hundred ethnically matched normal volunteers from
the same ethnic and geographical background of the
patients without any history of ocular or systemic diseases
served as controls. The controls were examined by direct
ophthalmoscopy, thorough examination of optic disc,
intraocular tension, gonioscopy, automated visual field
analysis and RNFL analysis with the help of scanning laser
polarimetry (SLP) and did not have any signs or symp-
toms of glaucoma The mean age of the controls was 53.86
± 8.92 years varying between 40 years and 80 years. The
patient and control samples were age matched (t = 0.877,
df = 298, p = 0.3812).
Around 10.0 ml of peripheral blood was collected from
the patients and normal volunteers by venipuncture with
informed consent. Genomic DNA was prepared from
whole blood using the conventional phenol-chloroform
method [29]. The study protocol adhered to the tenets of
the Declaration of Helsinki and was approved by the Insti-
tutional Review Board.
Polymerase chain reaction (PCR)
PCR was carried out in a total volume of 25.0 μl contain-
ing 50–100 ng genomic DNA, 0.4 μM of each primer, 0.2
mM of each dNTP, appropriate concentration of MgCl2,
and 0.5 unit of Taq polymerase (Invitrogen, Carlsbad, CA)
in a thermocycler (GeneAmp-9700, PE Applied Biosys-
tems). All the coding exons along with the intron-exon
boundaries were amplified using appropriate primers
(Table 2).
OPTC screening by single stranded conformational 
polymorphism (SSCP) and denaturing high-performance 
liquid chromatography (DHPLC)
The PCR products were run in the pre-cast (12.5% or
15%) SSCP gels. The experimental conditions were
adjusted as per the recommendations of the manufacturer
(Amersham, Piscataway, USA). All the patient samples (n
= 200) were screened for allelic variation by SSCP. PCR
products showing mobility shift were sequenced for char-
acterizing the variation. Among the four nucleotide vari-
ants identified, two (c.313A>G, p.Glu66Gly & c.382 T>C,
Table 2: Primer sequences and PCR conditions for amplifying coding sequence of OPTC
Primer Sequence Location Anneal temp. (°C) Mg2+conc. (mM) Length of PCR 
product (bp)
Forward (5'-3') Reverse (5'-3')
2aF-GTGGAGTAAATCTGCGAGCC 2aR-GGCAGAACTTCAAAGGAATC Exon 2 50 1.5 264
2bF-CTGAAGGGATTCTCAGTCCCATCTG 2bR-CTCCCAGTGTCATGCAGGGAATGT Exon 2 62 2.0 313
3F-GTTCCCAGAGTCCAAAGTTAAG 3R-GGTCATAGCTGCTTGGCCTATG Exon 3 54 1.5 275
4F-CAGATGGCCATGGTTCAGACAC 4R-GTGTTGGTGACTGTCCTAGTG Exon 4 58 2.0 333
5F-GACAAGGAAAGATAGTGTGTTCTG 5R-GTGGGTGGTGGAGGTGATAGATAG Exon 5 60 2.0 310
6F-CCACCTGTCTCTGGTCTCATAG 6R-CATCCTCCACGCTGTTTATCACC Exon 6 56 1.5 233
7F-CTGATGTGAGCCTTTGGTGCTGC 7R-GATAAGGAATTGGGCTTTATGGC Exon 7 62 2.0 334BMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
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p.Ile89Thr) were screened in controls (n = 100) by dHPLC
(The WAVE system, Transgenomic Inc., Omaha, USA)
under partially denaturing conditions. Prior to loading,
the amplicons were subjected to heteroduplex formation
and subsequently run under melting temperatures calcu-
lated from the WAVEMAKER™ software (version 4.1). The
DNA samples containing the variant alleles were used as
positive controls in the experiment. Variants were
observed as heteroduplex peaks.
DNA sequencing and bioinformatic analysis
The amplicons were column-purified using Qiagen PCR-
purification kit (Qiagen, Hilden, Germany), and the
patient samples showing mobility shift in SSCP were fur-
ther characterized by sequencing using the BigDye termi-
nation chemistry (version 3.1) in an ABI 3130XL capillary
DNA sequencer (Applied Biosystems, Foster City, CA) fol-
lowing manufacturer's protocol. The data was analysed
using SEQUENCING ANALYSIS software (version 5.2).
The observed nucleotide sequences in the patients were
compared to the OPTC  wild type sequence [GenBank:
NM_014359] for variations using Pair wise BLAST [30].
All novel mutations detected in OPTC were checked for
their functional relevance by the SIFT (Sorting Intolerant
From Tolerant)[31] homology tool, using related
sequences of plants and animals from a BLAST search of
GenBank to predict whether a substitution was likely to
have any phenotypic effect (Table 1). It essentially pre-
dicts the potential of a substituted amino acid to be dele-
terious in a protein sequence. A score less than 0.05 is the
benchmark of deleterious change [32]. Generations of any
cryptic splice site for any nucleotide variation was checked
using ESE finder (exon splicing enhancer finder) [33] or
RESQUE-ESE (relative enhancer and silencer classification
by unanimous enrichment) [34]. ESEfinder is a predictive
analysis derived from functional in vivo and in vitro sys-
tematic evolution of ligands by exponential enrichment
(SELEX) and statistical analysis [35]. RESCUE-ESE pre-
dicts which sequences have ESE activity by statistical anal-
ysis of exon-intron and splice site junction [36].
RNADraw [37] was used to predict the deviation from the
normal RNA secondary structure for the synonymous var-
iation (p.Phe162Phe).
Screening of control samples
Among the four nucleotide variants identified (c.919T>C,
p.Leu268Pro) only one caused change in a restriction site
(Bpu10 I). Therefore, this variant was screened in controls
by an RFLP assay using the restriction enzyme (New Eng-
land BioLabs, Boston, MA). The silent change (c.602C>T,
p.Phe162Phe) was screened by direct sequencing to make
sure that apparently innocuous variant was not present in
any control sample. The other two variants (c.313A>G,
p.Glu66Gly & c.382 T>C, p.Ile89Thr) which could be eas-
ily discriminated from wild type alleles by dHPLC was
screened in the controls by this method for convenience
and speed.
Site directed mutagenesis
Opticin constructs in pEGFPN1 mammalian expression
vector (kindly gifted by Dr. Michael Walter, Dept. of Med-
ical Genetics, University of Alberta) were initially isolated
from a dam+ strain. The oligonucleotide used for changing
C to T at 602nd nucleotide in OPTC cDNA was 5'- GCC
TAC CTG TAT GCA CGC TTT AAC CGC ATC AGC CGT
ATC AG -3' and 5'- CTG ATA CGG CTG ATG CGG TTA
AAG CGT GCA TAC AGG TAG GC -3'. Site-directed muta-
genesis was performed using the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA)
according to the manufacturer's protocol. After the reac-
tion was over, the residual product contained only the
nicked mutated plasmid without any starting material,
which was then transformed into XL10-GOLD ultra compe-
tent cells (A derivative of XL2 Blue MRF', Stratagene, La
Jolla, CA, USA) supplied by Stratagene. The transforma-
tion reaction in E. coli XL10-GOLD was carried out as per
the protocol provided by the manufacturer (Stratagene, La
Jolla, CA, USA). Plasmid isolation was done for both
c.602C and c.602T variant cloned in pEGFPN1 vector
using QIAGEN plasmid midi kit following the protocol
provided by manufacturers (Qiagen, Germany). The selec-
tion of the mutant clone as designed was confirmed by
sequencing the inserts within the mutagenized recom-
binant clone.
Mammalian cell culture
The human retinal pigment epithelium cell line RPE8319
(kind gift from Dr. Frans Cremers, University Medical
Center, Nijmegen, The Netherlands) was maintained in
DMEM (Dulbecco's modified Eagle Medium, GIBCO
BRL) at pH 7.4 supplemented with 10% fetal bovine
serum (GIBCO BRL) containing penicillin/streptomycin/
gentamycin in the presence of 5% CO2 at 37°C. Transient
transfection of human RPE cell lines was performed with
the Lipofectamine 2000 system according to the manufac-
turer's instructions (Invitrogen, Carlsbad, CA). Cells were
harvested after 40 hours of transfection, both for RNA
extraction for QRTand protein lysate preparation for west-
ern blot.
RNA extraction and cDNA preparation
Total RNA was isolated from the transfected or untrans-
fected RPE cells using TRIZOL (Invitrogen, Carlsbad, CA).
Two micrograms of total RNA was reverse-transcribed
using first strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA), in a total volume of 20 μl and stored at -
20°C until use.BMC Molecular Biology 2007, 8:21 http://www.biomedcentral.com/1471-2199/8/21
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Quantitative RT-PCR for OPTC c.602C and c.602T 
variant expression
The mRNA expression of normal (c.602C) and mutant
(c.602T) variant of OPTC was determined by real-time RT-
PCR in the 7500 Real Time PCR System (Applied Biosys-
tems, Foster City, CA) using SYBR Green Jumpstart Taq
Ready Mix (Sigma, St.Louis, MO). The following primers
were used: OPTC TF 5' CTCTGCCCGTGCTGCCCAGT 3',
OPTC TR 5' GGCAAAGGCCCCGGGATAGA 3' and
human  β-actin F 5'-TGACGGGGTCACCCACACTGT-
GCCCATCTA-3', human β-actin R 5'-CTAGAAGCATT-
GCGGTGGACGATGGAGGG-3'. The threshold cycle CT of
duplicate samples was determined using 7500 System
SDS software (Applied Biosystems, Foster City, CA). The
levels of both variants (c.602C & c.602T) of OPTC were
normalized to β-actin levels by calculating the ΔCTvalue,
which is the CT (threshold cycle) of the housekeeping
gene (β-actin) subtracted from the CT of the target gene
(OPTC). As OPTC mRNA is reportedly expressed in RPE
cells, we further normalize the data by calculating the
ΔΔCT value which is a subtraction of ΔCTvalue of untrans-
fected cells from each ΔCT value of both cells transfected
with c.602C & c.602T variant of OPTC. The mean ΔΔCT
value of each group (c.602C & C.602T) was represented in
corresponding figure (Fig 4A). All calculations were done
according to the published paper in 2001 by Giulietti et
al. [38].
Western Blot analysis
For western blot analysis transfected or untransfected RPE
cells were harvested in TBST [50 mM Tris-HCl (pH7.5), 15
mM EDTA, 150 mM NaCl, 0.1% TritonX-100], the lysis
buffer, supplemented with protease inhibitor cocktail (1
ul/106 cell; Sigma, St.Louis, MO) by freeze-fracture. Cell
extracts were then subjected to Bradford assay for total
protein estimation that would be necessary for equal load-
ing of cell lysate. The whole cell lysates were resolved in
10–12% SDS-PAGE in constant current and the gel was
transferred to PVDF membrane (Amersham Inc, The
Netherlands). After transfer the membrane was stained
with Ponceau-S solution and the gel with Coomassie blue
to ensure efficient transfer of the proteins to the mem-
brane. The membrane was blocked with 5% BSA in TBST
for at least 2 hrs at room temperature followed by addi-
tion of human specific opticin antibody (kind gift from
Dr. Paul Bishop, University of Manchester, UK) and beta-
actin (Sigma, St. Louis, MO) antibody (1:500–1000 dilu-
tion), raised in rabbit and mouse respectively, for over-
night reaction at 4–8°C. Then the membrane was washed
with TBST (0.05% of tween-20 in TBS) thrice for 10–15
mins each time. After that suitable secondary antibody
(goat anti mouse or anti rabbit) conjugated with ALP or
HRP (1:1000 dilution) was added and incubated for 3 hrs
at room temperature. Next, the membrane was washed
again with TBST 6 times for 10 mins each. In case of the
ALP fused secondary antibodies the membrane was
treated with BCIP/NBT (Genei, India) at pH 8.8 for 15–20
mins. For HRP fused secondary antibodies the membrane
was treated with TMB/H2O2 (Genei, India) for 10–15
mins. Colored bands were observed in the membrane due
to chromogenic reaction.
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